PE20141337A1 - Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida - Google Patents
Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamidaInfo
- Publication number
- PE20141337A1 PE20141337A1 PE2014000672A PE2014000672A PE20141337A1 PE 20141337 A1 PE20141337 A1 PE 20141337A1 PE 2014000672 A PE2014000672 A PE 2014000672A PE 2014000672 A PE2014000672 A PE 2014000672A PE 20141337 A1 PE20141337 A1 PE 20141337A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- benzamide
- imidazol
- pyridinyl
- trifluoro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
SE REFIERE A UNA FORMA DE DOSIFICACION SOLIDA QUE COMPRENDE: A) UN NUCLEO QUE COMPRENDE 4-METIL-3-[[4-(3-PIRIDINIL)-2-PIRIMIDINIL]-AMINO]-N-[5-(4-METIL-1H-IMIDAZOL-1-IL)-3-(TRIFLUORO-METIL)-FENIL]-BENZAMIDA (NILOTINIB) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO Y EXCIPIENTES; Y B) UN POLIMERO TAL COMO HIDROXI-PROPIL-METIL-CELULOSA EN UNA CANTIDAD DE 7 A 13% EN LA COMPOSICION QUE RECUBRE DICHO NUCLEO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION. DICHA COMPOSICION ES DE LIBERACION INMEDIATA SIENDO UTIL EN EL TRATAMIENTO DE LEUCEMIA MIELOIDE CRONICA, TUMORES ESTROMALES GASTROINTESTINALES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161559281P | 2011-11-14 | 2011-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20141337A1 true PE20141337A1 (es) | 2014-10-16 |
Family
ID=47324402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014000672A PE20141337A1 (es) | 2011-11-14 | 2012-11-12 | Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP2779995A1 (es) |
JP (1) | JP6275645B2 (es) |
KR (1) | KR20140093230A (es) |
CN (1) | CN103930094A (es) |
AR (1) | AR088844A1 (es) |
BR (1) | BR112014011518A2 (es) |
CA (1) | CA2855503A1 (es) |
CL (1) | CL2014001247A1 (es) |
CO (1) | CO6960546A2 (es) |
EA (1) | EA201490960A1 (es) |
GT (1) | GT201400094A (es) |
HK (1) | HK1197025A1 (es) |
IL (1) | IL232480A0 (es) |
IN (1) | IN2014DN03416A (es) |
MA (1) | MA35636B1 (es) |
MX (1) | MX2014005874A (es) |
PE (1) | PE20141337A1 (es) |
SG (2) | SG11201401476TA (es) |
TN (1) | TN2014000177A1 (es) |
TW (1) | TWI574690B (es) |
WO (1) | WO2013074432A1 (es) |
ZA (1) | ZA201402756B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
CZ2017821A3 (cs) | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Léková forma obsahující krystalický nilotinib |
JP7378279B2 (ja) | 2019-11-18 | 2023-11-13 | 日本化薬株式会社 | ニロチニブを有効成分とする医薬錠剤及びその製造方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
GT200600315A (es) | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
GT200600316A (es) | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
EP1923053A1 (en) * | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
US20100136097A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
WO2012164578A1 (en) * | 2011-06-02 | 2012-12-06 | Hetero Research Foundation | Compositions and methods for preparing immediate release formulations of nilotinib |
-
2012
- 2012-11-12 SG SG11201401476TA patent/SG11201401476TA/en unknown
- 2012-11-12 SG SG10201707768RA patent/SG10201707768RA/en unknown
- 2012-11-12 BR BR112014011518A patent/BR112014011518A2/pt not_active IP Right Cessation
- 2012-11-12 EA EA201490960A patent/EA201490960A1/ru unknown
- 2012-11-12 MX MX2014005874A patent/MX2014005874A/es unknown
- 2012-11-12 EP EP12798500.0A patent/EP2779995A1/en not_active Withdrawn
- 2012-11-12 JP JP2014541363A patent/JP6275645B2/ja not_active Expired - Fee Related
- 2012-11-12 CN CN201280055937.8A patent/CN103930094A/zh active Pending
- 2012-11-12 CA CA2855503A patent/CA2855503A1/en not_active Abandoned
- 2012-11-12 WO PCT/US2012/064610 patent/WO2013074432A1/en active Application Filing
- 2012-11-12 PE PE2014000672A patent/PE20141337A1/es not_active Application Discontinuation
- 2012-11-12 KR KR1020147012521A patent/KR20140093230A/ko not_active Application Discontinuation
- 2012-11-12 AR ARP120104259A patent/AR088844A1/es unknown
- 2012-11-12 IN IN3416DEN2014 patent/IN2014DN03416A/en unknown
- 2012-11-13 TW TW101142278A patent/TWI574690B/zh not_active IP Right Cessation
-
2014
- 2014-04-15 ZA ZA2014/02756A patent/ZA201402756B/en unknown
- 2014-04-25 TN TNP2014000177A patent/TN2014000177A1/en unknown
- 2014-05-05 IL IL232480A patent/IL232480A0/en unknown
- 2014-05-07 MA MA36991A patent/MA35636B1/fr unknown
- 2014-05-13 CL CL2014001247A patent/CL2014001247A1/es unknown
- 2014-05-14 CO CO14103891A patent/CO6960546A2/es unknown
- 2014-05-14 GT GT201400094A patent/GT201400094A/es unknown
- 2014-10-21 HK HK14110470A patent/HK1197025A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
TW201325594A (zh) | 2013-07-01 |
IL232480A0 (en) | 2014-06-30 |
AU2012339829B2 (en) | 2016-05-12 |
MX2014005874A (es) | 2014-06-23 |
TN2014000177A1 (en) | 2015-09-30 |
EP2779995A1 (en) | 2014-09-24 |
AU2012339829A1 (en) | 2014-05-29 |
SG11201401476TA (en) | 2014-10-30 |
CN103930094A (zh) | 2014-07-16 |
WO2013074432A1 (en) | 2013-05-23 |
CL2014001247A1 (es) | 2014-10-17 |
AR088844A1 (es) | 2014-07-10 |
KR20140093230A (ko) | 2014-07-25 |
HK1197025A1 (en) | 2015-01-02 |
TWI574690B (zh) | 2017-03-21 |
CA2855503A1 (en) | 2013-05-23 |
MA35636B1 (fr) | 2014-11-01 |
SG10201707768RA (en) | 2017-10-30 |
CO6960546A2 (es) | 2014-05-30 |
JP6275645B2 (ja) | 2018-02-07 |
ZA201402756B (en) | 2015-04-29 |
EA201490960A1 (ru) | 2014-08-29 |
BR112014011518A2 (pt) | 2017-05-16 |
JP2014533283A (ja) | 2014-12-11 |
GT201400094A (es) | 2017-09-28 |
NZ623844A (en) | 2016-09-30 |
IN2014DN03416A (es) | 2015-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201300309A (es) | Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos | |
PE20120626A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
CL2016000816A1 (es) | Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras. | |
NZ739339A (en) | Apoptosis signal-regulating kinase inhibitor | |
CL2013000884A1 (es) | El compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino, modulador del factor de crecimiento de fibroblastos (fgf); composicion farmaceutica, util en el tratamiento del cancer. | |
PE20141855A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
EA201291421A1 (ru) | Пероральные фармацевтические лекарственные формы, содержащие дабигатрана этексилат и его фармацевтически приемлемые соли | |
CR20120061A (es) | Tableta | |
PH12016500989B1 (en) | Crystalline salt of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonists | |
PH12016500988B1 (en) | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists | |
PE20141337A1 (es) | Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida | |
AR093635A1 (es) | Inhibidores de la tirosina quinasa de bruton, metodo de tratamiento, compuesto, combinacion, formulacion | |
MX2015012386A (es) | Inhibidores de la cinasa cdk9. | |
HRP20171295T1 (hr) | Derivat 6-okso-1,6-dihidro-piridazina za upotrebu za liječenje hepatocelularnog karcinoma (hcc) | |
IL182419A0 (en) | Use of 4- (4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms | |
TN2013000440A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
CN302200130S (zh) | 烟盒(超薄型正面圆角) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |